ArticleJCI insight2020
Apelin increases atrial conduction velocity, refractoriness, and prevents inducibility of atrial fibrillation.
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- The Impact of the Apelinergic System on the Cardiovascular System.International journal of molecular sciences · 2025Review
- Multi-omics reveals mechanism of Qi-Po-Sheng-Mai granule in reducing atrial fibrillation susceptibility in aged rats.Chinese medicine · 2025Article
- Skeletal Muscle as a Mediator of Interorgan Crosstalk During Exercise: Implications for Aging and Obesity.Circulation research · 2025Review
- Gene expression profiles, potential targets and treatments of cardiac remodeling.Molecular and cellular biochemistry · 2025Review
- The association between adipokines dysregulation and the occurrence of atrial fibrillation and obese patients, is it relevant?Archivos de cardiologia de Mexico · 2024Review
- Targeting the apelin system for the treatment of cardiovascular diseases.Cardiovascular research · 2023Review
- Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion.Biomedicines · 2023Review
- Adiposity-associated atrial fibrillation: molecular determinants, mechanisms, and clinical significance.Cardiovascular research · 2023Review
- TIMP3 induces gene expression partly through PI3K and their association with vascularization and heart rate.Frontiers in cardiovascular medicine · 2023Article
- Microvascular and proteomic signatures overlap in COVID-19 and bacterial sepsis: the MICROCODE study.Angiogenesis · 2022Observational
- The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals.Clinical proteomics · 2022Article
- ELABELA acts as a protective biomarker in patients with atrial fibrillation.Journal of thoracic disease · 2021Article
- The therapeutic potential of apelin in kidney disease.Nature reviews. Nephrology · 2021Review
- Association Between Apelin and Atrial Fibrillation in Patients With High Risk of Ischemic Stroke.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
Previous studies have shown an association between elevated atrial NADPH-dependent oxidative stress and decreased plasma apelin in patients with atrial fibrillation (AF), though the basis for this relationship is unclear. In the current study, RT-PCR and immunofluorescence studies of human right atrial appendages (RAAs) showed expression of the apelin receptor, APJ, and reduced apelin content in the atria, but not in plasma, of patients with AF versus normal sinus rhythm. Disruption of the apelin gene in mice increased (2.4-fold) NADPH-stimulated superoxide levels and slowed atrial conduction velocities in optical mapping of a Langendorff-perfused isolated heart model, suggesting that apelin levels may influence AF vulnerability. Indeed, in mice with increased AF vulnerability (induced by chronic intense exercise), apelin administration reduced the incidence and duration of induced atrial arrhythmias in association with prolonged atrial refractory periods. Moreover, apelin decreased AF induction in isolated atria from exercised mice while accelerating conduction velocity and increasing action potential durations. At the cellular level, these changes were associated with increased atrial cardiomyocyte sodium currents. These findings support the conclusion that reduced atrial apelin is maladaptive in fibrillating human atrial myocardium and that increasing apelin bioavailability may be a worthwhile therapeutic strategy for treating and preventing AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.